PMN310 is a humanized monoclonal antibody which targets a conformational epitope present on misfolded amyloid-beta (Aβ). Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA, discusses the in vivo data gathered as part of the preclinical development of this investigational antibody. Two animal models were used to interrogate the protective capabilities of PMN310: APP/L transgenic mice and wildtype mice injected intracerebroventricularly with Aβ oligomers. Introduction of toxic oligomers was shown to inhibit short-term memory formation, resulting in an inability to distinguish new from familiar objects. However, when this group was treated with PMN310, memory formation was protected. In the APP/L model, systemic administration of PMN310 preserved memory and learning in the water maze task. This interview took place during the AAN 2023 Annual Meeting in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
